GlucoTrack, Inc.
GlucoTrack, Inc. (GCTK) Stock Overview
Explore GlucoTrack, Inc.’s financial performance, market position, analyst ratings, and future outlook.
GCTK Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of GlucoTrack, Inc. (GCTK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $2.72.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.17 and a market capitalization of 3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Mr. Paul V. Goode Ph.D.
11
8 Ariel Sharon Street, Or Yehuda
2013